Application of DWI in Diagnosis of Prostate Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

103 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-06-12

Study Completion Date

2018-06-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study compared the performance of different models of multiple b-value DWI in diagnosing prostate cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture

NCT06901492

PSMA PET/CT Prostate Cancer MpMRI

NOT_YET_RECRUITING NA

MR Microstructural Imaging for Prostate Cancer Diagnosis

NCT07249281

Prostate Cancer Diffusion MRI

RECRUITING

The Value of Dual-parametric Magnetic Resonance Combined With Regional Saturation Biopsy in Patients With Suspected Prostate Cancer

NCT06824259

Prostate Cancer

ACTIVE_NOT_RECRUITING NA

68Ga-PSMA PET/MRI in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk

NCT06494696

Prostate Cancer

RECRUITING

Comparison Of DIR-MRI And DCE-MRI In Detection Of Prostate Cancer: A Pilot Study

NCT02939456

Cancer of the Prostate

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diffusion weighted imaging (DWI) plays an important role in the diagnosis and stratification of prostate cancer. Traditional DWI apply the apparent diffusion coefficient (ADC) to reflect the diffusion of tissue water, which is a parameter calculated by a monoexponential model with 2b values. In recent years, the development of multiple b-value DWI facilitates the appearance of many new mathematical models. Different models have different features, but their value of applications in prostate cancer still need to be confirmed. This study was aiming to: (1) compare the parameters derived from monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model between prostate cancer and benign prostatic hyperplasia; (2) compare the difference of these parameters between low-grade (Gleason score ≤ 3+4) and high-grade (Gleason score ≥ 4+3) cancer; (3) find whether these parameters derived from new models are superior to ADC derived from traditional monoexponetial model.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer Benign Prostatic Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

prostate cancer

The patient was pathologically diagnosed with prostate cancer

MRI

Intervention Type DIAGNOSTIC_TEST

monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model

benign prostatic hyperplasia

The patient was pathologically diagnosed with benign prostatic hyperplasia

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

monoexponential model, intravoxel incoherent motion (IVIM) model and stretched exponential model

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The exam including T1WI、T2WI and multiple b-value DWI.
2. Comfired by pathology as prostate cancer or benign prostatic hyperplasia in one month after the MRI exam.

Exclusion Criteria

* 1.No Gleason score data. 2.Awful quality of imagings or artifacts affectting diagnosis. 3.No lesion larger than 0.5cm. 4.Any surgery or treatment before MRI exam. 5.Biopsy in 4 weeks before MRI exam.

Eligible Sex

MALE

Accepts Healthy Volunteers

No